Q3 2026 AtriCure, Inc. Earnings Conference Call - ATRICURE INC

Financial Performance:

• Third quarter 2026 worldwide revenue reached $154.5 million, a 15% year-over-year increase, with constant currency growth of 15.1%; U.S. revenue grew 17.1% to $128 million.
• Net income was $4.1 million compared to a $0.3 million net loss in the prior year; Adjusted EBITDA rose 50.6% to $26.8 million.
• Gross margin improved 180 basis points year-over-year to 77.3%, driven by favorable product and geographic mix.
• Operating expenses totaled $115 million (up 13.7% YoY); excluding a $4.5 million PFA co-development milestone, R&D expenses increased 20.6% to support clinical trials, while SG&A grew only 5.9%, demonstrating operating leverage.
• Cash flow remained positive with $19.2 million generated during the quarter; the company ended with $187 million in cash and investments.
• Specific segment performance: Open ablation grew 20.8% to $43 million; Appendage management grew 13.5% to $51.6 million; Pain management surged 34.6% to $28.1 million; Minimally invasive ablation declined to $5.4 million.

Guidance and Future Outlook:

• Raised full-year 2026 revenue guidance to $606 million–$610 million (13.4%–14.1% growth).
• Reiterated full-year net income guidance and raised Adjusted EBITDA outlook to $91 million–$94 million; Adjusted EPS guidance increased to $0.40–$0.46.
• Full-year 2026 gross margin expected in the upper 76% range, though Q4 may see slight sequential pressure due to the normalization of geographic mix and new manufacturing facility costs.
• Management expects international growth to remain slower than the U.S. in the near term but anticipates a return to higher growth rates in 2027 driven by new product availability and team development.
• Confidence remains high that the company will finish the year ahead of the initial guidance and outpace long-range targets.

Business Segments and Product Lines:

• Open Ablation: Strong adoption of the Encompass clamp, now comprising >70% of U.S. open ablation revenue; TRAC AF registry data shows 91% freedom from AFib at one year.
• Appendage Management: AtroClip Flex Mini (and Pro Mini) drove growth, accounting for nearly 50% of U.S. appendage revenue; received FDA 510K clearance for a new 30mm Flex Mini device launching in December; Flex Mini V in development for late 2027 launch.
• Pain Management: 33% revenue growth led by CryoSphere Max; Cryo XT for amputation procedures surpassed 1,000 devices sold with >$1 million in Q3 revenue; steady adoption in sternotomy procedures (mid-single-digit penetration).
• Minimally Invasive Ablation: Continued pressure in the standalone AFib treatment market as PFA catheter therapy gains focus.
• Clinical Trials: BOXX NOAAF trial enrollment at 880 patients (targeting completion before year-end) with data readout expected Spring 2027; LEAPS trial continues with >6,500 patients to evaluate stroke reduction.

Market and Competitive Landscape:

• Competitive Dynamics: Acknowledged new competitors in the appendage management space but maintains confidence in superior technology and market share; introduced a smaller 30mm device to differentiate from competitors offering 35mm+ clips.
• Market Trends: STS quality metrics for concomitant AFib treatment (effective Jan 1, 2027) are expected to drive phased adoption, particularly in CABG patients.
• Clinical Evidence: Strong data from LAX-2 trial (56% stroke reduction in high-risk patients) and historical LAOS-3 trial support the efficacy of surgical LAA management compared to mixed evidence in endovascular treatments.
• Geography: U.S. market remains the primary growth engine; Europe faces funding headwinds, while Asia Pacific and other markets grew 6.9%.

Risks and Challenges:

• International Headwinds: Persistent challenges in certain European markets due to funding constraints and slower adoption; reimbursement friction noted in the UK previously, though traction is returning.
• Hybrid Ablation: Continued weakness in the U.S. hybrid/standalone AFib treatment market as PFA catheters capture share.
• Clinical Trial Delays: Reliance on successful readouts from BOXX NOAAF and LEAPS trials for future growth catalysts.
• Regulatory: PFA co-development agreement involves milestone payments impacting quarterly expenses; future PMA approval anticipated for BOXX in mid-2028.

Management Commentary and Tone:

• Tone is confident and optimistic, highlighting "strong momentum," "expanded profitability," and the "breadth" of the business.
• Management emphasized that the 30mm AtroClip and new Cryo XT innovations demonstrate a commitment to listening to customer feedback and driving innovation.
• Leadership noted that while international markets face near-term headwinds, the company is "better positioned than ever" to capitalize on long-term growth in under-penetrated markets.

Analyst Questions and Answers:

• Open Ablation Adoption: Management clarified that most U.S. sites are already trained; growth is driven by buzz around ease of use and emerging clinical evidence rather than pre-metric training spikes.
• New Accounts vs. Existing: Pain management growth is primarily volume-based from existing accounts, with new accounts contributing only a few percent per quarter; Cryo XT is ramping as expected.
• 30mm Flex Mini: Differentiation lies in being the first device <35mm, leaving less implant behind, addressing specific customer requests for smaller profiles.
• STS Quality Metrics: Expected to be a phased rollout (starting with a "OR" metric, potentially becoming an "AND" over years), targeting CABG patients who currently have lower AFib treatment rates.
• Sales Force: Atricure claims the largest cardiac surgery sales force (~350 people) in the market; expansion plans for 2027 are driven by preparation for BOXX PMA approval rather than direct competitor response.
• R&D Spending: R&D is expected to remain elevated in 2027 to support new trials for the dual-energy platform and continued follow-up on BOXX/LEAPS.
• Evidence vs. Competitors: Management highlighted that cardiac surgery has robust randomized trial evidence (LAX-2, LEAPS, LAOS-3) supporting LAA management, contrasting with mixed endovascular data.

Other Key Points:

• The 30mm AtroClip Flex Mini launch is scheduled for December 2026.
• Cryo XT is expected to see acceleration in 2027 with significant acceleration anticipated in 2028.
• New manufacturing facility costs impacted Q3 gross margin, but the favorable U.S. mix offset these costs significantly.
• Management plans to continue investing in growth-related R&D, including a dual-energy platform trial expected to initiate in 2027.
• The company has surpassed 1,000 units sold for Cryo XT in amputation procedures, marking a key early adoption milestone.